Lobg Tablet contains Lobeglitazone Sulfate 0.5 mg, an oral antidiabetic agent belonging to the thiazolidinedione class. It is primarily indicated for the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic medications, to improve glycemic control. Lobeglitazone acts as a selective agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in peripheral tissues such as adipose tissue, muscle, and liver. This mechanism facilitates increased glucose uptake and utilization, thereby reducing insulin resistance, a key pathological feature of type 2 diabetes. Clinical studies have demonstrated that Lobg Tablet effectively lowers fasting plasma glucose and HbA1c levels, contributing to better long-term glycemic management. The medication is generally well tolerated; however, patients should be monitored for potential adverse effects including weight gain, edema, and rare occurrences of heart failure exacerbation. It is contraindicated in patients with a history of hypersensitivity to thiazolidinediones, active liver disease, or severe cardiac impairment. Regular liver function tests and cardiovascular assessments are recommended during therapy. Lobg Tablet should be used as part of a comprehensive diabetes management plan that includes diet, exercise, and regular blood glucose monitoring to optimize therapeutic outcomes.